Discovery on Target 2026 has ended. This guide stays up as the record of who was there. Next: Discovery on Target 2027, Oct 18–21, 2027 in Boston

Innovative discovery technologies at Discovery on Target 2026

Sep 28 – Oct 1, 2026 Boston, MA ~1.1k attendees Website

76 organizations at Discovery on Target 2026 present work in innovative discovery technologies: 44 technology and service providers, 19 drug developers and 13 academic, government and non-profit bodies. Between them they bring 125 presentations to the program. Most represented: Pfizer, AstraZeneca and University of California, San Francisco. As of Oct 8, 2026.

All 510 organizations at Discovery on Target 2026 →

Showing 1–7 of 76 organizations

Organization	Discovery on Target 2026 Attendance
Pfizer New York, NY
pfizer.com Large pharma Global pharmaceutical company developing medicines and vaccines in oncology, inflammation and immunology, internal medicine and rare diseases.	Chair Tue Sep 29 1:45pm–1:50pm Chairperson's Remarks Emerging Drug Targets Talk Tue Sep 29 2:20pm–2:50pm Discovery of Potent and Brain-Penetrant Inverse Agonists for GPR61, an Orphan GPCR Emerging Drug Targets Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Bristol Myers Squibb, Amgen +3 more Novel drug modalitiesInnovative discovery technologies Panel Wed Sep 30 7:30am–8:15am Modern GPCR-Targeted Drug Discovery Lead Generation Strategies · with Computational Therapeutics Discovery Talk Wed Sep 30 11:50am–12:20pm A GIPR Small-Molecule Antagonist for Obesity Lead Generation Strategies Chair Wed Sep 30 2:00pm–2:05pm Chairperson's Remarks Lead Generation Strategies Talk Wed Sep 30 2:35pm–3:05pm Fragment Screening and Hit Optimization for an Orphan GPCR Using 19F-NMR and SPR Techniques Lead Generation Strategies Panel Thu Oct 1 7:30am–8:15am Building the Next Generation of DEL Datasets for AI Lead Generation Strategies Talk Thu Oct 1 9:35am–10:05am Extracting Actionable SAR from Primary DEL Screens to Drive Early Lead Optimization Lead Generation Strategies Talk Thu Oct 1 3:30pm–4:00pm Antibody-Drug Conjugate Immunogenicity: Current Landscape and Strategies to De-Risk Development Next-Generation Conjugates
AstraZeneca Cambridge, UK
astrazeneca.com Large pharma Global biopharmaceutical company with medicines in oncology, cardiovascular, respiratory, immunology and rare diseases.	Chair Mon Sep 28 1:30pm–1:35pm Chairperson's Remarks Symposium: Induced Proximity-Based Drug Discovery Panel Tue Sep 29 11:05am–12:05pm Defining Next-Generation Radioligand Therapies: From Molecular Design to Clinical and Commercial Success Radioligand Therapies · with Normunity, Lumina Pharmaceuticals, Ratio Therapeutics +2 more Talk Tue Sep 29 1:50pm–2:20pm From Imaging to Impact: Practical Frameworks for Personalized Dosimetry in Radioligand Therapy Radioligand Therapies Talk Tue Sep 29 2:50pm–3:20pm DegDig: Digging the Fate of Proteins under Degrader Control by Multiplexed Target‑Guided Proteomics in a 384 Well Format Innovative Discovery Technologies Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Bristol Myers Squibb, Amgen +3 more Novel drug modalitiesInnovative discovery technologies Talk Wed Sep 30 9:05am–9:35am Advancements in ADCs: Current Trends in Bioconjugation and Site-Specific Conjugation Strategies Next-Generation Conjugates Talk Wed Sep 30 2:05pm–2:35pm Reduced Time-Point Dosimetry in Radioconjugate Therapy: From Preclinical Models to Clinical Translation Radioligand Therapies Panel Wed Sep 30 3:05pm–4:05pm From Target to Therapy: Science, Strategy, and Scalability Radioligand Therapies · with Perceptive, Curium, Mariana Oncology +1 more Panel Thu Oct 1 7:30am–8:15am Connect the DOTs: Career Growth Opportunities Plenary · with Avacta Therapeutics
University of California, San Francisco San Francisco, CA
	Panel Mon Sep 28 5:00pm–6:00pm Where and How Can Open Source AI/ML Learning Impact Drug Development? Symposium: Generative AI/Machine Learning-Driven Drug Design · with PsiThera, Ginkgo Bioworks, Eli Lilly +3 more Talk Tue Sep 29 10:35am–11:35am Ninhydrin as a Covalent Warhead-Targeting Arginine Lead Generation Strategies Talk Tue Sep 29 11:35am–12:05pm Snapshots of the Cell Surface: Mapping Protein Neighborhoods Using Contact-dependent Antibody Mapping (contactMAP) Antibodies Against Challenging Targets Talk Wed Sep 30 11:50am–12:20pm Targeted Degradation of Extracellular Proteins via Induced Shedding Novel Drug Modalities Talk Wed Sep 30 12:20pm–12:50pm Making "n=1" Therapies Accessible for All with Computational Target Prediction Innovative Discovery Technologies Talk Thu Oct 1 10:05am–10:35am Structure-Guided Engineering of a Conformation-Specific Antibody–Drug Conjugate for AML Antibodies Against Challenging Targets Talk Thu Oct 1 10:35am–11:05am Chemical Strategies to Expand the Therapeutic Window for Targeted Radiotherapy Radioligand Therapies
Novartis Basel, Switzerland
novartis.com Large pharma Global pharmaceutical company; Novartis Biomedical Research is its drug discovery arm.	Panel Mon Sep 28 10:45am–11:30am Implementation of Computational Strategies for Driving Proximity-Induced Therapies Symposium: Induced Proximity-Based Drug Discovery · with Barcelona Supercomputing Center, InduPro, Foghorn Therapeutics Talk Tue Sep 29 2:20pm–2:50pm From PSMA to What’s Next: Evolving the Radioligand Target Landscape Radioligand Therapies Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Bristol Myers Squibb, Amgen +3 more Novel drug modalitiesInnovative discovery technologies Talk Wed Sep 30 2:05pm–2:35pm Exploring the Impact of Ligand and Payload Design on ADC Therapeutic Index Using Quantitative Systems Pharmacology and Physiologically Based Pharmacokinetic Modeling Next-Generation Conjugates Panel Thu Oct 1 7:30am–8:15am Direct-to-Biology (D2B) Lead Generation Strategies
Bristol Myers Squibb Princeton, NJ
bms.com Large pharma Global biopharmaceutical company with medicines in oncology, immunology, cardiovascular disease and neuroscience.	Talk Tue Sep 29 8:35am–9:05am Advancing KRAS G12C Active-State Inhibition through Next-Generation Covalent Warhead Design Lead Generation Strategies Panel Tue Sep 29 5:00pm–6:00pm Tackling Difficult Drug Targets: Having a Modality-Agnostic & Technology-Nimble Approach Plenary · with Drug Hunter, Amgen, Novartis +3 more Novel drug modalitiesInnovative discovery technologies Panel Wed Sep 30 7:30am–8:15am Covalent Drug Design Strategies Lead Generation Strategies · with GSK Talk Thu Oct 1 12:20pm–12:50pm Direct-to-Biology Discovery of BMS-986526, an EP4 Agonist for the Treatment of Inflammatory Bowel Disease Lead Generation Strategies Talk Thu Oct 1 3:35pm–4:05pm Discovery of BMS-986196: A Brain-Penetrant, Covalent Inhibitor of Bruton’s Tyrosine Kinase (BTK) Emerging Drug Targets
Johnson & Johnson New Brunswick, NJ
jnj.com Large pharma Healthcare company whose Innovative Medicine segment, formerly Janssen, develops medicines in oncology, immunology and neuroscience.	Chair Tue Sep 29 8:30am–8:35am Chairperson's Remarks Emerging Drug Targets Panel Wed Sep 30 7:30am–8:15am Collaborative Conversations for Women in Science Plenary · with EMD Serono, Moderna Chair Wed Sep 30 9:00am–9:05am Chairperson's Remarks Novel Drug Modalities Talk Wed Sep 30 3:05pm–3:35pm Immunogenicity Mitigation for Biotherapeutics Discovery: Integrated Workflow of Tools and Assays for Diverse Modalities Innovative Discovery Technologies Panel Thu Oct 1 7:30am–8:15am Setting Up Collaborations & Partnerships Plenary · with Revolution Medicines
Massachusetts Institute of Technology Cambridge, Massachusetts
	Talk Wed Sep 30 9:35am–10:05am Antibody Discovery against Intrinsically Disordered Proteins Antibodies Against Challenging Targets Talk Wed Sep 30 11:50am–12:20pm Peptide–Small Molecule Conjugate Libraries for Hit Discovery and Catalyst Development Next-Generation Conjugates Panel Thu Oct 1 2:25pm–3:20pm Starting Up: Translating Lab Ideas into Commercial Impact Plenary · with Portal Biotechnologies, Kiral Medicines, AIRNA +3 more Talk Thu Oct 1 4:05pm–4:35pm Label-Free Single-Cell Buoyant Mass Profiling Uncovers Hidden T-Cell Heterogeneity and Predicts Immunotherapy Response Innovative Discovery Technologies